We developed a commercial partnership strategy for Respiro’s breath-based diagnostic platform in lung cancer. Respiro needed to know which pharma and biotech companies to approach first, and with what proposition. We scored and tiered a longlist of around 40 companies down to a shortlist of 15, then analysed their clinical pipelines and the existing companion diagnostic landscape to find specific programmes where the platform could fill a gap. We recommended a sequence from small biotech partnerships through to large pharma deals, and identified further opportunities in immunotherapy patient selection and brain metastasis risk.